Related Experiment Video
Updated: Apr 25, 2026
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
[Pilot study of intermittent administration of liposomal amphotericin B for chronic pulmonary aspergillosis]
Abstract:
Treatment for chronic pulmonary aspergillosis is difficult and frequently is required for prolong period. In outpatients setting, only voriconazole and itraconazole could be used. Since liposomal amphotericin B (L-AMB) demonstrated prolonged half-time, we have investigated the feasibility of L-AMB in outpatient setting. Three cases of chronic pulmonary aspergillosis were treated with intermittent administration of 2.5 mg/kg of L-AMB twice weekly for one month in outpatient settings. Improve of symptoms was attained in 2 of 3 cases. Improvement of chest images were in 2 of 3, improvement of laboratory test were in 2 of 3. Adverse events were only fatigue and short period of fever. No recurrence of pulmonary aspergillosis has been found after treatment. Intermittent administration of L-AMB in outpatient settings could be an option for pulmonary aspergillosis.
Insights
Intermittent liposomal amphotericin B (L-AMB) shows promise for treating chronic pulmonary aspergillosis in outpatient settings. This approach improved symptoms and imaging in most patients with minimal side effects.
Area of Science:
- Mycology
- Pulmonology
- Infectious Diseases
Background:
- Chronic pulmonary aspergillosis (CPA) treatment is challenging, often requiring long-term therapy.
- Current outpatient options for CPA are limited to oral azoles like voriconazole and itraconazole.
- Liposomal amphotericin B (L-AMB) has a prolonged half-life, suggesting potential for intermittent outpatient administration.
Observation:
- A feasibility study explored intermittent L-AMB for CPA in an outpatient setting.
- Three CPA patients received L-AMB at 2.5 mg/kg twice weekly for one month.
- This regimen was investigated due to the limitations of existing oral therapies.
Findings:
- Two out of three patients showed improvement in clinical symptoms.
- Radiological findings on chest imaging improved in two out of three patients.
- Laboratory test results also improved in two out of three cases, with mild adverse events like fatigue and fever.
Implications:
- Intermittent L-AMB administration may be a viable outpatient treatment option for CPA.
- This approach could offer an alternative for patients who cannot tolerate or do not respond to oral antifungal agents.
- Further research is warranted to confirm the efficacy and safety of this intermittent L-AMB regimen for CPA.
More Related Videos
06:43Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
Published on: January 13, 2016
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
